Literature DB >> 9613038

The peptide-binding strategy of the MHC class II I-A molecules.

B Reizis1, M Eisenstein, F Mor, I R Cohen.   

Abstract

Mesh:

Substances:

Year:  1998        PMID: 9613038     DOI: 10.1016/s0167-5699(97)01238-3

Source DB:  PubMed          Journal:  Immunol Today        ISSN: 0167-5699


× No keyword cloud information.
  5 in total

1.  Identification of amino acid residues of the T-cell epitope of Mycobacterium tuberculosis alpha antigen critical for Vbeta11(+) Th1 cells.

Authors:  A Kariyone; K Higuchi; S Yamamoto; A Nagasaka-Kametaka; M Harada; A Takahashi; N Harada; K Ogasawara; K Takatsu
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  An immunogenetic basis for the high prevalence of urogenital cancer in a free-ranging population of California sea lions (Zalophus californianus).

Authors:  Lizabeth Bowen; Brian M Aldridge; Robert Delong; Sharon Melin; Elizabeth L Buckles; Frances Gulland; Linda J Lowenstine; Jeffrey L Stott; Michael L Johnson
Journal:  Immunogenetics       Date:  2005-01-14       Impact factor: 2.846

3.  I-Ag7 is subject to post-translational chaperoning by CLIP.

Authors:  Cornelia H Rinderknecht; Ning Lu; Oliver Crespo; Phi Truong; Tieying Hou; Nan Wang; Narendiran Rajasekaran; Elizabeth D Mellins
Journal:  Int Immunol       Date:  2010-06-13       Impact factor: 4.823

4.  Common antigenicity between Japanese cedar (Cryptomeria japonica) pollen and Japanese cypress (Chamaecyparis obtusa) pollen, II. Determination of the cross-reacting T-cell epitope of cry j 1 and cha o 1 in mice.

Authors:  N Ohno; T Ide; M Sakaguchi; S Inouye; S Saito
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

5.  Class II multiformity generated by variable MHC- DRB region configurations in the California sea lion ( Zalophus californianus).

Authors:  Lizabeth Bowen; Brian M Aldridge; Frances Gulland; William Van Bonn; Robert DeLong; Sharon Melin; Linda J Lowenstine; Jeffrey L Stott; Michael L Johnson
Journal:  Immunogenetics       Date:  2004-03-02       Impact factor: 2.846

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.